Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on Anika Therapeutics (NASDAQ:ANIK) and increased the price target from $28 to $29.
January 03, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barrington Research analyst Michael Petusky has reaffirmed an Outperform rating on Anika Therapeutics and raised the price target from $28 to $29.
The increase in price target by Barrington Research suggests a positive outlook on Anika Therapeutics' stock, which could lead to a short-term increase in its stock price as investors react to the analyst's upgraded expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100